Search the Newsreel

Iovance Biotherapeutics (NASDAQ: IOVA) posts Q2 2026 $99.3M revenue

Iovance Biotherapeutics: Q2 Earnings Snapshot

Iovance Biotherapeutics (IOVA) reported a Q2 loss of $47.3 million, or 11 cents per share, with revenue reaching $99.3 million. The biotechnology company anticipates full-year revenue to be between $350 million and $370 million. This financial update was generated using data from Zacks Investment …

Enterprise value to EBIT forward of Iovance Biotherapeutics Inc – FWB:2LB

This article displays the Enterprise Value to EBIT forward for Iovance Biotherapeutics Inc (FWB:2LB) on the Frankfurt Stock Exchange. It indicates that the market is closed with no trades. The content is presented as a financial overview for the company.

Iovance Biotherapeutics (IOVA) Is Down 18.4% After Early Amtagvi Rollout Update - Has The Bull Case Changed?

Iovance Biotherapeutics (IOVA) Stock May Be Cheap As Sales Ramp Remains Key

Iovance Biotherapeutics (IOVA) stock is showing signs of being undervalued according to Simply Wall St's framework, despite a significant 5-year decline. The valuation hinges on the company's ability to generate reliable revenue from its therapies and control cash burn. While it scores well on …

Iovance Biotherapeutics (IOVA) Heads Into Earnings With Its T Cell Therapy Story And Valuation In Focus

Iovance Biotherapeutics (IOVA) is approaching its Q2 2026 earnings report on August 6, 2026, with investors focusing on its first FDA-approved T cell therapy for solid tumors. Despite recent share price pullbacks, the company shows strong short-term momentum and is considered significantly undervalued by …

Class Action Lawsuit Filed Against Iovance Biotherapeutics, Inc

A class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) on behalf of investors who suffered losses due to alleged securities fraud between May 9, 2024, and May 8, 2025. The lawsuit claims that Iovance made misleading statements about its growth …

Iovance Biotherapeutics (IOVA) Stock Looks Cheap On Sales While Returns Stay Weak

Iovance Biotherapeutics (IOVA) stock appears undervalued based on its sales multiple, trading at 6.4x sales compared to the biotech industry average of 10.5x and a tailored fair P/S ratio of 7.1x. Despite a recent rebound, long-term investors still face significant losses over five years, …

IOVA Stock Slides As Biotech Traders Watch Key Support

Iovance Biotherapeutics Inc. (IOVA) stock has dropped significantly, trading down 14.07% due to concerns over its cancer therapy pipeline. While the company has substantial cash reserves and modest debt, it remains unprofitable with high R&D spending. Traders are closely monitoring the $4 support level, …

Iovance Sets Aug. 6 Webcast to Discuss Second-Quarter Results

Iovance Biotherapeutics (NASDAQ: IOVA) announced it will host a conference call and live audio webcast on Thursday, August 6, 2026, at 8:30 a.m. ET to report its second quarter 2026 financial results and provide corporate updates. Investors can access the live or archived webcast …

Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) announced it will host a conference call and live audio webcast on Thursday, August 6, 2026, at 8:30 a.m. ET to discuss its second quarter 2026 financial results and provide corporate updates. The company is a biotechnology firm focused …

Iovance Biotherapeutics Inc (IOVA) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Iovance Biotherapeutics Inc (IOVA), noting its current score of 4.11 and its ranking within the Biotechnology & Medical Research industry. It details the company's beta value of 0.74, indicating less volatility than the S&P 500, and presents …

Will Iovance Biotherapeutics (IOVA) Report Negative Q2 Earnings? What You Should Know

Iovance Biotherapeutics Inc (IOVA) Institutional Confidence

Iovance Biotherapeutics Inc (IOVA) has an institutional shareholding score of 5.00, placing it 132nd out of 385 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 69.13%, marking an 11.55% increase quarter-over-quarter. MHR Fund Management LLC is listed as the largest …

BlackRock (IOVA holder) reports 33.4M Iovance Biotherapeutics shares, a 7.5% stake

BlackRock, Inc. has reported a 7.5% stake in IOVANCE BIOTHERAPEUTICS, INC. (IOVA), beneficially owning 33,366,587 shares as of June 30, 2026. The firm holds sole voting power over 32,842,318 shares and sole dispositive power over all 33,366,587 shares, with no single underlying client holding …

IOVA|Iovance Biotherapeutics Inc|Price:4.990|Chg%:-0.140

Iovance Biotherapeutics Inc. is a commercial biotechnology company focused on developing and delivering novel tumor-infiltrating lymphocyte (TIL) therapies for cancer patients. Their key product, Amtagvi, is an autologous T cell immunotherapy for unresectable or metastatic melanoma, used in conjunction with Proleukin. The company is …

Iovance Biotherapeutics Inc (IOVA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Iovance Biotherapeutics Inc (IOVA), noting that some detailed business segment data has not yet been disclosed by the company. It highlights that the vast majority of the company's revenue, $259.01 million (98.30%), is generated in the United …

Iovance Biotherapeutics Inc (IOVA) Income Statement: Quarterly and Annual Data

This article provides detailed quarterly and annual income statement data for Iovance Biotherapeutics Inc (IOVA), including metrics such as total revenue, cost of revenue, operating expenses, R&D expenses, operating profit, and net income. It also includes frequently asked questions about how to interpret the …

Iovance Biotherapeutics Inc Revenue Breakdown – MIL:1IOVA

Iovance Biotherapeutics Inc (MIL:1IOVA) generated 224.35 million EUR in revenue last year, with its Autologous Tumor Infiltrating Lymphocyte Cell Therapies segment being the primary contributor. The United States was the leading geographical source of revenue for the company. This marks an increase from the …

Iovance Biotherapeutics Inc (IOVA) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Iovance Biotherapeutics Inc (IOVA), with its current earnings forecast score being 7.80. Analysts have set an average price target of $9.00 for IOVA, with a strong buy consensus based on 10 analysts. The company also has an …

Iovance Biotherapeutics Market Sentiment

The article provides an overview of market sentiment for Iovance Biotherapeutics (IOVA), detailing analyst consensus, short interest, options flow, and recent analyst actions. Key signals suggest a "Buy" consensus from analysts, declining short interest, and a bullish options flow. The report also includes a …

Iovance Biotherapeutics stock hits 52-week high at $5.64

Iovance Biotherapeutics Inc. (IOVA) stock reached a new 52-week high of $5.64, demonstrating a 75% return over the past year and substantial gains in recent months. Despite a Q1 2026 earnings miss, the company's valuation appears undervalued according to InvestingPro, with significant revenue growth. …

Iovance Biotherapeutics (IOVA) Stock Looks Fully Priced Despite Strong 117% Returns

Despite a significant 117.5% return year-to-date, Iovance Biotherapeutics (IOVA) stock appears to be fully priced, according to valuation checks and current trading multiples. While its P/S multiple of 8.6x is below the broader biotech industry average, it is considered overvalued relative to its estimated …

Why Did IOVA Stock Gain Pre-Market Today?

Iovance Biotherapeutics (IOVA) stock gained over 5% in pre-market trading due to encouraging early results from a pilot study of its tumor-infiltrating lymphocyte therapy, lifileucel, for aggressive soft tissue sarcomas. The company also reported strong fourth-quarter earnings with $65 million in Amtagvi revenue, and …

Iovance Biotherapeutics (NASDAQ:IOVA) shares jump 18% as Amtagvi sales test approaches

Iovance Biotherapeutics (NASDAQ:IOVA) shares surged 18% due to investor focus on the upcoming sales performance of its drug Amtagvi. The company gained approximately $344 million in equity value last week, nearing its full-year revenue guidance midpoint. Management anticipates significant revenue growth for Amtagvi in …

Iovance Gives 17 New Employees Options That Vest Over 3 Years

Iovance Biotherapeutics (NASDAQ: IOVA) granted inducement stock options covering 139,930 shares to 17 new non-executive employees on July 16, 2026. The options have an exercise price of $4.66 per share, equal to the closing price on the grant date, and vest over a three-year …

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Biotherapeutics, Inc. announced the grant of inducement stock options for 139,930 shares to seventeen new non-executive employees on July 16, 2026. These awards were made under the company's Amended and Restated 2021 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The stock …

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Why Iovance Biotherapeutics (IOVA) Is Up 5.7% After AMTAGVI-Driven Q1 Revenue Jump And Share Plan

IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%

Iovance (IOVA) Q1 2026 Earnings Transcript

Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Lags Revenue Estimates

Iovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Iovance Biotherapeutics (IOVA) Down 2.1% Since Last Earnings Report: Can It Rebound?

Earnings call transcript: Iovance Biotherapeutics Q4 2025 sees revenue beat, stock surges

IOVANCE BIOTHERAPEUTICS, INC. SEC 10-Q Report